Niktimvo™ (Axatilimab-Csfr) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Niktimvo (axatilimab‑csfr) for moderate-to-severe chronic GVHD in patients ≥40 kg who have failed at least two prior systemic therapies (must include a corticosteroid plus one of: bortezomib, ibrutinib, an immunosuppressant such as cyclosporine/mycophenolate/tacrolimus, ruxolitinib, belumosudil, or rituximab), when prescribed by or in consultation with a transplant specialist and dosed per FDA labeling, with initial authorization up to 12 months. Continuation requires documented clinical benefit and FDA-consistent dosing (reauthorizations up to 12 months); use for acute GVHD or other non‑cGVHD indications is not medically necessary.

"Dosing must be in accordance with the United States Food and Drug Administration approved labeling."

Sign up to see full coverage criteria, indications, and limitations.